← Forte Biosciences overview

Forte Biosciences vs AbbVie: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Forte Biosciences Inc (FBRX)

Q3 2026
▲2▼1

Forte acquired by argenx for $77/share after positive vitiligo data

  • Acquisition by argenx Forte Biosciences was acquired by argenx for $77 per share in cash, about $2.2 billion, an 86% premium. The deal closed August 27, 2026, giving shareholders the cash price.

    This is the main event that drove FBRX's price in Q3 2026.

  • Positive Phase 1 vitiligo data Positive Phase 1 vitiligo data for FB102 made Forte an attractive takeover target, leading to the argenx acquisition and folding FB102 into argenx's immunology pipeline.

    The clinical data was the catalyst that attracted the acquirer.

  • Investor-rights investigations Several investor-rights law firms are investigating whether $77 is fair, citing possible insider benefits and deal terms discouraging rival bids. Such probes rarely change an agreed cash deal.

    This is the main risk that could affect the deal price or timing.

  • End of standalone trading With the buyout complete, FBRX no longer trades on its own clinical results. The stock's price is now tied to the cash deal, and future performance depends on argenx.

    This marks the end of FBRX as an independent company, a key structural change.

August 2026
▲2

Forte Biosciences bought by argenx for $77 a share in cash

  • argenx agrees to buy Forte for $77/share cash argenx is acquiring Forte Biosciences for $77.00 per share in cash, a deal worth about $2.2 billion. That price is the main thing setting FBRX's value now: once a cash buyout is agreed, the stock tends to trade near the offer rather than on its own drug news.

    The agreed cash buyout is the single force that now determines FBRX's price.

  • Deal closes, ending FBRX as a standalone stock argenx completed the acquisition on August 27, 2026, folding Forte's FB102 antibody into its immunology pipeline. Shareholders get the $77 cash per share. With the deal done, FBRX no longer trades on its own clinical results — its story is now argenx's pipeline plans.

    Completion is the final event that locks in the buyout outcome for shareholders.

  • Law firms question whether $77 is fair Several investor-rights law firms are investigating whether the $77 sale is fair, citing possible insider benefits and deal terms that may discourage rival bids. They may seek a higher price or more disclosure. This creates some chance of a bump, but such probes rarely change an agreed cash deal.

    It is the main counterweight to the buyout price and could affect what shareholders ultimately receive.

Latest
▲2

Forte Biosciences bought by argenx for $77 a share in cash

  • argenx agrees to buy Forte for $77/share cash argenx is acquiring Forte Biosciences for $77.00 per share in cash, a deal worth about $2.2 billion. That price is the main thing setting FBRX's value now: once a cash buyout is agreed, the stock tends to trade near the offer rather than on its own drug news.

    The agreed cash buyout is the single force that now determines FBRX's price.

  • Deal closes, ending FBRX as a standalone stock argenx completed the acquisition on August 27, 2026, folding Forte's FB102 antibody into its immunology pipeline. Shareholders get the $77 cash per share. With the deal done, FBRX no longer trades on its own clinical results — its story is now argenx's pipeline plans.

    Completion is the final event that locks in the buyout outcome for shareholders.

  • Law firms question whether $77 is fair Several investor-rights law firms are investigating whether the $77 sale is fair, citing possible insider benefits and deal terms that may discourage rival bids. They may seek a higher price or more disclosure. This creates some chance of a bump, but such probes rarely change an agreed cash deal.

    It is the main counterweight to the buyout price and could affect what shareholders ultimately receive.

July 2026
▲3

argenx's $2.2B cash buyout of Forte Biosciences drives FBRX

  • argenx to acquire Forte for $77/share cash argenx agreed to buy Forte for $77 per share in cash, about $2.2 billion, an 86% premium to Forte's recent average price. This puts a hard cash floor under the stock and is the main reason it jumped. Both boards approved the deal, expected to close in the third quarter of 2026.

    This is the single new event that explains the period's move and sets the stock's value near the offer price.

  • Deal shifts focus to completion, not standalone growth With a buyer in place, FBRX now trades on whether the tender offer closes, not on its own drug pipeline. The stock sits just below the $77 offer, so the remaining gap is mostly deal-completion risk. That caps further upside unless a higher bid appears.

    It tells readers what now drives the shares after the buyout, which is the key takeaway for anyone holding or considering FBRX.

  • Positive vitiligo data made Forte an attractive target Forte's FB102 showed positive Phase 1 vitiligo results earlier in July, which lifted the stock and helped attract argenx. The buyout price reflects a premium to the average price since that data, showing the trial success was a direct driver of the deal value.

    It explains the underlying reason argenx wanted Forte and why the offer price is where it is.

▲3

argenx's $2.2B cash buyout of Forte Biosciences drives FBRX

  • argenx to acquire Forte for $77/share cash argenx agreed to buy Forte for $77 per share in cash, about $2.2 billion, an 86% premium to Forte's recent average price. This puts a hard cash floor under the stock and is the main reason it jumped. Both boards approved the deal, expected to close in the third quarter of 2026.

    This is the single new event that explains the period's move and sets the stock's value near the offer price.

  • Deal shifts focus to completion, not standalone growth With a buyer in place, FBRX now trades on whether the tender offer closes, not on its own drug pipeline. The stock sits just below the $77 offer, so the remaining gap is mostly deal-completion risk. That caps further upside unless a higher bid appears.

    It tells readers what now drives the shares after the buyout, which is the key takeaway for anyone holding or considering FBRX.

  • Positive vitiligo data made Forte an attractive target Forte's FB102 showed positive Phase 1 vitiligo results earlier in July, which lifted the stock and helped attract argenx. The buyout price reflects a premium to the average price since that data, showing the trial success was a direct driver of the deal value.

    It explains the underlying reason argenx wanted Forte and why the offer price is where it is.

AbbVie Inc (ABBV)

Q3 2026
▲2▼2

AbbVie Q3: Guidance Cut, Pricing Threats Offset Drug Approvals

  • Q2 Beat and Raised Guidance AbbVie beat Q2 estimates and raised full-year revenue and profit guidance, driven by Skyrizi and Rinvoq (now ~47% of revenue) plus neuroscience growth. This showed the core business remains strong.

    This is new positive news that lifted sentiment during the quarter.

  • Label Expansions and Pipeline Wins EU and FDA approvals expanded labels across oncology, aesthetics, immunology, and Parkinson's. Pipeline wins for epcoritamab, etentamig, Qulipta, and Rinvoq, plus Citadel's 547% stake increase, boosted sentiment.

    These new approvals and pipeline successes are fresh positive drivers.

  • EPCORE Trial Miss and Guidance Cut The EPCORE DLBCL-1 trial missed its survival endpoint, triggering a profit guidance cut and a 4% share drop. This was a major setback for the pipeline and investor confidence.

    This new negative event directly caused a guidance cut and stock decline.

  • Pricing Pressures and Apogee Dilution Trump's price-cut demands threaten pricing power, J&J's oral psoriasis pill could erode Skyrizi share, and the $10.9B Apogee acquisition dilutes EPS through 2027 with profits only by 2032. Oncology sales fell 2.8% as Imbruvica plunged 27.1%.

    These new risks weigh on future earnings and stock valuation.

August 2026
▲3▼1

AbbVie's August: Pipeline Wins and Guidance Raises Offset Pricing and Competition Risks

  • Raised Guidance and Revenue Beat AbbVie reported a 10.2% revenue beat and raised profit guidance, with Skyrizi and Rinvoq now over 47% of revenue (~$31B) and neuroscience guidance lifted to ~$12.7B. This shows strong core business momentum.

    This is the main positive force driving the stock, reflecting better-than-expected financial performance and outlook.

  • Pipeline and Regulatory Wins Epcoritamab cut progression risk by 51%, Temab-A received two FDA breakthrough designations, Boey won EU approval, and 340B rebate relief was granted. These expand future growth prospects.

    These pipeline and regulatory successes are new positive developments that support long-term growth.

  • Citadel's Big Stake Increase Citadel raised its stake in AbbVie by 547%, signaling strong confidence from a major institutional investor. This can boost market sentiment and attract other investors.

    This is a new vote of confidence from a prominent investor, which can positively influence the stock price.

  • Pricing and Competition Threats Trump's demand for U.S. price cuts threatens AbbVie's pricing power, while J&J's oral psoriasis pill approved in China could take share from Skyrizi. Apogee dilution also weighs.

    These are key risks that could pressure revenue and market share, acting as a counterweight to the positive drivers.

Latest
▲5

AbbVie's earnings beat and pipeline wins outweigh Apogee dilution

  • Quarterly results beat as new drugs offset Humira's decline AbbVie's revenue rose 10.2% to $16.99 billion and adjusted earnings per share jumped 22.9% to $3.65, with Skyrizi and Rinvoq each up about 24%. Management raised full-year profit guidance, showing the company is growing again despite Humira's 35.9% sales drop. This reassures investors and supports the stock.

    The latest earnings show the core business is growing and guidance was raised, a direct positive for the stock.

  • Epcoritamab combination cuts lymphoma progression risk by 51% In a late-stage trial, AbbVie and partner Genmab's drug epcoritamab plus standard chemotherapy reduced the risk of disease worsening or death by 51% in newly diagnosed diffuse large B-cell lymphoma. This is the first such success for a bispecific antibody in frontline treatment, strengthening AbbVie's cancer pipeline and lifting hopes for a new growth driver.

    A major clinical win in a large cancer market adds a potential new revenue stream and boosts investor confidence.

  • FDA grants two breakthrough designations for Temab-A The FDA gave AbbVie's experimental antibody-drug conjugate Temab-A two Breakthrough Therapy Designations, for colorectal and non-small cell lung cancer. This speeds up development and signals the drug may offer a big advantage over existing treatments. It adds to AbbVie's growing oncology pipeline and supports long-term growth.

    Breakthrough designations can accelerate approval and highlight pipeline strength, a positive for future sales.

  • EU approves Boey, a fast-acting short-duration frown-line treatment European regulators approved Boey, the first rapid-onset, short-duration neurotoxin for frown lines, with effects starting in as little as eight hours and lasting two to three weeks. This expands AbbVie's aesthetics portfolio with a differentiated product and could capture new demand, supporting the stock.

    A new approved product in aesthetics adds revenue potential and competitive edge.

  • AbbVie selected for 340B rebate pilot, easing discount burden The Trump administration picked AbbVie as one of 10 drugmakers for a pilot that lets companies pay rebates after purchase instead of giving upfront discounts under the 340B program. This could improve cash flow and reduce compliance risk, a modest positive for the stock.

    The pilot may reduce upfront costs and regulatory friction for AbbVie.

September 2026
▲2▼2

AbbVie's Pipeline Wins Offset Apogee Dilution and Oncology Decline

  • Pipeline Momentum AbbVie reported multiple Phase 3 wins: etentamig for myeloma, Qulipta for menstrual migraine, and RINVOQ for vitiligo. EU approved Rinvoq for juvenile arthritis, and the FDA approved JUVMO for Parkinson's. Early-stage data for zumilokibart and ABBV-295 also showed promise.

    These pipeline successes signal future growth and strengthen AbbVie's competitive position.

  • Neuroscience Guidance Raised AbbVie raised its neuroscience revenue guidance to about $12.7 billion, with total revenue near $67.6 billion. This reflects confidence in its neuroscience portfolio and overall business strength.

    Higher guidance indicates management's optimism and potential for earnings growth.

  • Apogee Acquisition Dilutes Earnings The $10.9 billion Apogee acquisition will reduce earnings by $0.14 per share in 2026 and $0.46 in 2027, with profits not expected until 2032. This near-term dilution pressures the stock.

    The acquisition's dilution is a significant near-term headwind for earnings per share.

  • Oncology Sales Decline Oncology sales fell 2.8% as Imbruvica dropped 27.1% due to competition and IRA pricing. Newer drugs did not fully offset the decline, highlighting challenges in this segment.

    The decline in oncology revenue weighs on overall growth and profitability.

▲4

AbbVie's pipeline wins and new drug approvals drive growth outlook

  • FDA approves JUVMO for Parkinson's disease The FDA approved JUVMO (tavapadon), the first selective D1/D5 agonist for Parkinson's, with U.S. launch set for October 2026. This adds a differentiated neuroscience drug to AbbVie's portfolio, supporting future revenue growth and lifting investor confidence.

    A major new drug approval directly expands AbbVie's revenue base and pipeline strength.

  • Zumilokibart succeeds in Phase 2 atopic dermatitis trial AbbVie's zumilokibart met the main goal in a Phase 2 study for atopic dermatitis, and the mid-dose will move into final-stage testing. This strengthens the immunology pipeline and offers a potential new treatment for a common skin condition, supporting long-term growth.

    Positive mid-stage trial results advance a key pipeline candidate, signaling future revenue potential.

  • ABBV-295 shows promising weight loss and long half-life Phase 1 data for ABBV-295 showed up to 9.8% weight loss and an 11-12 day half-life, supporting less frequent dosing. This opens a new market for AbbVie in obesity care, a high-growth area, and could become a significant future sales driver.

    Early data support a potential best-in-class obesity drug, a major new growth opportunity.

  • RINVOQ shows sustained vitiligo repigmentation in Phase 3 Phase 3 data show RINVOQ produced continued skin repigmentation in vitiligo through 76 weeks with no new safety issues. This supports a potential new use for a key drug, expanding its label and adding a new revenue stream if approved.

    Late-stage data support a new indication for a major drug, enhancing its growth prospects.

▲3▼1

AbbVie's pipeline and label wins offset oncology and pricing headwinds

  • Qulipta hits Phase 3 goal in menstrual migraine Qulipta met the main goal and all secondary goals in a late-stage trial for menstrual migraine, a condition with no approved treatment. If approved, it opens a new market of over nine million U.S. patients, adding a fresh sales driver and supporting the stock.

    New clinical win expands a fast-growing drug into an untapped market, a clear positive for future revenue.

  • Rinvoq wins EU approval for juvenile arthritis European regulators approved Rinvoq for polyarticular juvenile idiopathic arthritis, its 11th EU use. This widens the label of a key growth drug already on track for about $10.2 billion in 2026 sales, reinforcing confidence in AbbVie's immunology growth.

    New regulatory approval directly expands a major growth drug's market and supports the bull case.

  • AI drug-discovery deals and EPKINLY approval AbbVie signed multi-year AI collaborations with Iambic and joined the AISB Bind network to speed up drug discovery, and Health Canada approved EPKINLY for relapsed follicular lymphoma. These broaden the pipeline and add a new approved use, supporting long-term growth.

    New partnerships and a new approval show pipeline expansion and fresh revenue potential.

  • Oncology sales fall on Imbruvica and IRA pricing First-half oncology sales dropped 2.8% to $3.28 billion as Imbruvica fell 27.1% on competition and Medicare drug-price changes. Newer drugs like Venclexta and Elahere grew but did not fully offset the decline, weighing on overall growth.

    A real counterweight: a key segment is shrinking due to competition and pricing pressure.

▲3▼1

AbbVie's pipeline and guidance wins offset Apogee dilution

  • Apogee acquisition dilutes near-term earnings AbbVie closed its $10.9 billion purchase of Apogee Therapeutics, adding an experimental immunology drug but cutting adjusted earnings by $0.14 per share in 2026 and $0.46 in 2027. Profit won't get a boost until 2032, so near-term investors see lower earnings and the stock faces pressure.

    This is the main new negative event this period and directly lowers reported earnings, a key driver of the stock price.

  • Etentamig succeeds in Phase 3 myeloma trial AbbVie's experimental blood-cancer drug etentamig met both main goals in a late-stage trial, with a 74% response rate versus 46% for standard care and a 60% lower risk of disease worsening. This strengthens the oncology pipeline and raises hopes for a new growth driver, supporting the stock.

    This is a major new clinical win that expands AbbVie's cancer franchise and improves long-term growth prospects.

  • Qulipta succeeds in menstrual migraine trial AbbVie's migraine drug Qulipta hit the main goal in a Phase 3 trial for menstrual migraine, reducing migraine days with a convenient dosing schedule. Qulipta sales already grew 31% to $350 million last quarter, so a new use could add revenue and lift the stock.

    This is a new positive trial result that could expand the label and sales of an already fast-growing drug.

  • Neuroscience outlook raised on broad growth AbbVie lifted its 2026 neuroscience revenue forecast to about $12.7 billion and total revenue to roughly $67.6 billion, after first-half neuroscience sales jumped 21.8%. Strong demand across Vraylar, Botox, Qulipta, Ubrelvy and Vyalev gives investors more confidence in future profits, pushing the stock up.

    This is a new guidance raise that directly improves revenue expectations and signals broad-based demand strength.

▲3▼1

AbbVie's pipeline and franchise expansion offset profit-guidance cut

  • Citadel boosts AbbVie stake by 547% Ken Griffin's Citadel bought 2.68 million more ABBV shares, a 547% increase, at an average of $214.90. A major fund raising its bet signals confidence in AbbVie's long-term value and can draw other investors in, supporting the stock price.

    Large institutional buying is a fresh, concrete signal of confidence that can lift investor sentiment and demand for the shares.

  • New lung cancer data strengthens oncology pipeline AbbVie presented promising early data for several experimental lung cancer drugs at a major conference, with high response rates and manageable side effects. This broadens its pipeline beyond immunology and neuroscience, giving investors another potential growth engine and supporting the stock.

    Fresh clinical progress on multiple oncology programs adds a new growth pillar, which can improve the long-term earnings outlook.

  • Skyrizi submitted for easier Crohn's dosing in Europe AbbVie asked European regulators to approve Skyrizi as a subcutaneous (under-the-skin) induction treatment for Crohn's disease, based on positive trial data. If approved, it offers patients a more convenient option and extends Skyrizi's reach, supporting future sales and the stock.

    A regulatory filing that could widen a key drug's use is a concrete pipeline expansion, not just a repeat of past results.

  • J&J's oral psoriasis pill approved in China Johnson & Johnson won Chinese approval for Icotyde, a once-daily pill for plaque psoriasis, a market with over 8.4 million patients where AbbVie's Skyrizi competes. A convenient oral option could take share from injectables like Skyrizi, weighing on AbbVie's growth prospects in China.

    This is a new competitive threat in a large market that could pressure sales of a key AbbVie drug.

▲2▼2

AbbVie's core drugs stay strong, but pricing pressure and pipeline setback weigh

  • Trump demands drug price cuts President Trump sent letters to major drugmakers, including AbbVie, demanding U.S. prescription price cuts within 60 days. This threatens future pricing power and revenue, pushing the stock down as investors worry about lower profits.

    This is a new regulatory threat that directly pressures AbbVie's pricing and future earnings.

  • Skyrizi and Rinvoq fuel growth AbbVie's newer immunology drugs Skyrizi and Rinvoq now make up over 47% of total revenue, with combined sales expected to exceed $31 billion this year. Their rapid growth is replacing declining Humira sales and supports the stock's long-term value.

    This shows the core business is successfully transitioning beyond Humira, a key driver of future revenue.

  • Neuroscience outlook raised AbbVie raised its 2026 neuroscience revenue forecast to about $12.7 billion, driven by strong sales of Vraylar, migraine drugs Ubrelvy and Qulipta, and Botox Therapeutic. This diversification adds a growing revenue stream and boosts investor confidence.

    This is a new positive update showing another part of AbbVie's business is performing well and raising guidance.

  • Epcoritamab trial fails survival goal Genmab and AbbVie confirmed that the Phase 3 trial of epcoritamab for a type of lymphoma did not meet its main overall survival goal. This pipeline setback could delay or reduce the drug's potential, weighing on sentiment.

    This is a new negative pipeline event that could hurt future oncology revenue prospects.

July 2026
▲3▼1

AbbVie's Q2 Beat and EU Approvals Offset by Trial Miss and Profit Guidance Cut

  • EU Approvals Expand Drug Labels AbbVie won European approvals for TEPKINLY in follicular lymphoma, Boey for frown lines, and RINVOQ for alopecia areata, broadening its oncology, aesthetics, and immunology offerings. These label expansions can drive future revenue growth.

    New approvals are a key positive development that can boost investor confidence and future sales.

  • Q2 Earnings Beat and Guidance Raise AbbVie reported Q2 EPS of $3.65 and revenue of $16.99 billion, beating estimates. Management raised full-year revenue guidance by $300 million, citing strong growth in Skyrizi, Rinvoq, and neuroscience.

    The earnings beat and guidance raise show operational strength and support the bull case.

  • Voluntary Pricing Deals Reduce Uncertainty AbbVie entered voluntary most-favored-nation pricing agreements, which lessen regulatory uncertainty around drug pricing. This proactive step may stabilize the pricing environment and reduce political risk.

    Reduced regulatory uncertainty is a positive for the stock as it removes a potential overhang.

  • Trial Miss and Profit Guidance Cut The Phase 3 EPCORE DLBCL-1 trial for epcoritamab missed its overall survival endpoint, hurting oncology sentiment. Additionally, a $291 million acquired IPR&D charge led AbbVie to cut full-year adjusted earnings guidance, sending shares down 4%.

    The trial failure and earnings guidance cut are significant negatives that pressured the stock.

▲2▼2

AbbVie beats Q2, raises revenue outlook, but full-year profit guidance cut

  • Q2 beat and raised revenue guidance AbbVie beat Q2 estimates with $3.65 EPS and $16.99B revenue, and raised full-year revenue guidance by $300M on strong Skyrizi, Rinvoq and neuroscience growth. This shows the core business is performing well, supporting the stock's long-term value.

    This is the main new positive event this period, directly driving the stock's fundamental outlook.

  • Full-year profit guidance lowered Despite the revenue beat, AbbVie cut its full-year adjusted earnings outlook, partly due to a $291M charge for acquired IPR&D and milestone expenses. This disappointed investors and caused shares to fall 4%, as it signals near-term profit pressure.

    This is the key negative event this period, explaining the immediate stock drop and investor concern.

  • EU approval of RINVOQ for alopecia areata AbbVie won European approval for RINVOQ in severe alopecia areata, expanding its immunology franchise. This adds a new revenue stream and reinforces RINVOQ's growth potential, which is positive for the stock.

    This is a new regulatory win that expands the market for a key drug, supporting future sales.

  • Epcoritamab trial setback The Phase 3 EPCORE DLBCL-1 trial for epcoritamab missed its overall survival endpoint in the U.S., a setback for AbbVie's oncology pipeline. This could delay or reduce the drug's potential, weighing on sentiment.

    This is a new negative pipeline event that affects future growth prospects.

▲3▼1

AbbVie's pipeline wins approvals but faces trial setback and new competition

  • EU approval of TEPKINLY for follicular lymphoma The European Commission approved AbbVie's TEPKINLY combination for relapsed follicular lymphoma, a chemotherapy-free option that cut progression risk by 79%. This expands AbbVie's oncology portfolio and adds a new revenue stream, supporting long-term growth.

    New approval directly boosts AbbVie's oncology franchise and future sales.

  • EU approval of Boey for frown lines Allergan Aesthetics, part of AbbVie, won EU approval for Boey, a fast-acting botulinum toxin for frown lines. This strengthens AbbVie's aesthetics business and offers a new treatment option, potentially driving revenue growth.

    New product approval expands AbbVie's aesthetics portfolio and revenue potential.

  • Voluntary drug-pricing deals with Trump administration AbbVie agreed to voluntary most-favored-nation pricing with the Trump administration. While this may lower prices for some drugs, AbbVie's newer immunology drugs Skyrizi and Rinvoq are expected to offset Humira's decline, and the deal reduces regulatory uncertainty.

    New pricing agreement affects AbbVie's revenue but is manageable given strong new drugs.

  • Epcoritamab trial misses overall survival endpoint Genmab and AbbVie confirmed that the Phase 3 EPCORE DLBCL-1 trial did not meet its primary overall survival endpoint in the U.S. This setback could delay or reduce the drug's potential in this indication, weighing on sentiment.

    New negative trial result directly impacts AbbVie's oncology pipeline and investor confidence.

Q2 2026
▲2▼2

AbbVie's $10.9B Apogee Deal and Drug Wins Lift Shares to 52-Week High

  • Apogee Acquisition AbbVie agreed to buy Apogee Therapeutics for $10.9 billion in cash, gaining a potential rival to Dupixent. The deal is funded from operating cash flow, so no new debt is needed.

    This major acquisition is a key new event that could drive future growth and investor sentiment.

  • Drug Label Expansions and Phase 3 Wins AbbVie expanded the labels for Skyrizi and Rinvoq and reported positive Phase 3 results. This pushed the stock to a 52-week high and added $43 billion in market value.

    These clinical and regulatory successes directly boosted the stock price and market value.

  • Congressional Probe into China Trials A bipartisan congressional probe into AbbVie's China clinical trials could raise compliance costs and delay drug pipelines. This adds uncertainty and potential headwinds for the company.

    This regulatory risk is a new negative factor that could weigh on the stock.

  • Decelerating Growth of Key Drugs Growth of key drugs Skyrizi and Rinvoq is slowing, which could pressure the stock's rich valuation. Investors may worry about future revenue growth.

    Slowing growth is a fundamental concern that could limit upside for the stock.

June 2026
▲2▼2

AbbVie's $10.9B Apogee Deal and Drug Wins Lift Shares to 52-Week High

  • Apogee Acquisition AbbVie agreed to buy Apogee Therapeutics for $10.9 billion in cash, gaining a potential rival to Dupixent. The deal is funded from operating cash flow, so no new debt is needed.

    This major acquisition is a key new event that could drive future growth and investor sentiment.

  • Drug Label Expansions and Phase 3 Wins AbbVie expanded the labels for Skyrizi and Rinvoq and reported positive Phase 3 results. This pushed the stock to a 52-week high and added $43 billion in market value.

    These clinical and regulatory successes directly boosted the stock price and market value.

  • Congressional Probe into China Trials A bipartisan congressional probe into AbbVie's China clinical trials could raise compliance costs and delay drug pipelines. This adds uncertainty and potential headwinds for the company.

    This regulatory risk is a new negative factor that could weigh on the stock.

  • Decelerating Growth of Key Drugs Growth of key drugs Skyrizi and Rinvoq is slowing, which could pressure the stock's rich valuation. Investors may worry about future revenue growth.

    Slowing growth is a fundamental concern that could limit upside for the stock.

▲2▼2

AbbVie hits 52-week high on Apogee deal and drug approvals, but China probe and slowing drug growth weigh

  • Apogee acquisition and expanded drug labels drive record high AbbVie agreed to buy Apogee Therapeutics for $10.9 billion, adding a promising immunology drug. It also won approvals to expand Skyrizi and Rinvoq to new patient groups. These moves strengthen future growth and pushed the stock to a 52-week high, adding $43 billion in market value in a week.

    This is the main reason the stock hit a new high and reflects the biggest new development this period.

  • US Congress opens bipartisan probe into AbbVie's China clinical trials A House committee is investigating AbbVie's clinical trials in China, including sites linked to the Chinese military and in Xinjiang. While no illegal conduct is alleged, the probe could lead to tighter oversight, higher compliance costs, and restrictions on trial locations, potentially delaying drug pipelines and hurting the stock.

    This is a new risk that could negatively affect the stock and was not in earlier reports.

  • Growth of key drugs Skyrizi and Rinvoq shows signs of slowing Skyrizi's growth decelerated to 29.2% from 31.9%, and Rinvoq's growth slowed to 20.2% from 28.6%. These drugs are critical to AbbVie's post-Humira strategy, and any sustained slowdown could pressure the stock's valuation, which already prices in high growth.

    This is a new concern about the company's growth engine that could weigh on the stock.

  • Positive late-stage trial results and new drug approvals bolster pipeline AbbVie reported positive Phase 3 data for venetoclax in leukemia and epcoritamab in lymphoma, and won approvals for MAVIRET in hepatitis C, SKYRIZI in pediatric psoriasis, and a new neurotoxin Boey. These advances strengthen the company's oncology and aesthetics portfolios, supporting long-term revenue growth.

    These are new clinical and regulatory wins that reinforce AbbVie's pipeline and future sales potential.

▲3

AbbVie's $10.9B Apogee buy expands immunology pipeline

  • Apogee acquisition adds promising immunology drug AbbVie agreed to buy Apogee Therapeutics for $10.9 billion in cash, gaining zumilokibart, a potential rival to Dupixent for eczema and asthma. The deal strengthens AbbVie's immunology franchise and pipeline, which investors view as a positive for long-term growth.

    This is the main new event driving ABBV's stock and future prospects.

  • Deal funded without debt, preserving financial flexibility AbbVie will pay for Apogee entirely from operating cash flow, avoiding new debt. This keeps its balance sheet strong and reduces financial risk, which supports the stock price.

    Shows the acquisition is financially manageable and not a strain.

  • Near-term earnings dilution, but long-term growth The deal won't add to adjusted earnings per share until 2032, so it may slightly weigh on near-term profits. However, it positions AbbVie for future growth in immunology, balancing the short-term cost with long-term benefit.

    Highlights the trade-off investors are weighing.

  • Analysts see reasonable premium and strategic fit Citi and other analysts said the 49% premium is not excessive given Apogee's strong data and scarce immunology assets. The deal also fits with AbbVie's existing commercial infrastructure, supporting a positive view.

    Analyst validation reinforces the market's positive reaction.